3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Unknown
1
Not yet recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Dermatologic
1
Conditions
Leukemia, Myeloid, Acute
82
Myelodysplastic Syndromes
71
Precursor Cell Lymphoblastic Leukemia-Lymphoma
69
Leukemia, Lymphocytic, Chronic, B-Cell
69
Lymphoma, Non-Hodgkin
63
Hodgkin Disease
62
Leukemia
56
Multiple Myeloma
52
Lymphoma
46
Lymphoma, Follicular
44
Lymphoma, Mantle-Cell
41
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
41
Lymphoma, Large B-Cell, Diffuse
40
Lymphoma, B-Cell, Marginal Zone
39
Myeloproliferative Disorders
36
Burkitt Lymphoma
35
Congenital Abnormalities
29
Lymphoma, Large-Cell, Immunoblastic
27
Leukemia, Myelomonocytic, Chronic
27
Hematologic Neoplasms
27
Leukemia, Myeloid, Chronic-Phase
26
Waldenstrom Macroglobulinemia
22
Neoplasms, Plasma Cell
22
Leukemia, Myeloid, Accelerated Phase
22
Anemia, Refractory, with Excess of Blasts
22
Graft vs Host Disease
21
Primary Myelofibrosis
20
Recurrence
19
Leukemia, Prolymphocytic
19
Dendritic Cell Sarcoma, Interdigitating
18
Interventions
Mycophenolic Acid
2
vedolizumab
1
Ursodeoxycholic Acid
1
Steroids
1
Sofosbuvir
1
Ribavirin
1
Prednisone
1
Photopheresis
1
Methylprednisolone Hemisuccinate
1
Methylprednisolone
1
Methoxsalen
1
Infliximab
1
Azathioprine
1
Adrenal Cortex Hormones
1
3-(2-(2-tert-butylphenylaminooxalyl)aminopropionylamino)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 2
×
Hepatitis
×
Mycophenolic Acid
×
Clear all
NCT07619898
2026-06-02
PHOENIX-ECP
Therakos LLC
Phase 2
Not yet recruiting
112 enrolled
NCT04810156
2022-12-14
I-HEP
Herlev Hospital
Phase 2
Unknown
60 enrolled